Cargando…
Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma
BACKGROUND: There is no remedial strategy other than definitive chemoradiotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) who are not eligible to undergo surgical treatment. AIM: To introduce a novel therapy called endoscopic debulking resection (EdR) followed by additiv...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516645/ https://www.ncbi.nlm.nih.gov/pubmed/36187386 http://dx.doi.org/10.4251/wjgo.v14.i9.1758 |
_version_ | 1784798751906332672 |
---|---|
author | Ren, Li-Hua Zhu, Ye Chen, Rong Shrestha Sachin, Mulmi Lu, Qin Xie, Wei-Hua Lu, Tong Wei, Xiao-Ying Shi, Rui-Hua |
author_facet | Ren, Li-Hua Zhu, Ye Chen, Rong Shrestha Sachin, Mulmi Lu, Qin Xie, Wei-Hua Lu, Tong Wei, Xiao-Ying Shi, Rui-Hua |
author_sort | Ren, Li-Hua |
collection | PubMed |
description | BACKGROUND: There is no remedial strategy other than definitive chemoradiotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) who are not eligible to undergo surgical treatment. AIM: To introduce a novel therapy called endoscopic debulking resection (EdR) followed by additive chemoradiotherapy (CRT) and evaluate its efficacy and safety. METHODS: Advanced, inoperable ESCC patients between 1 January 2015 and 30 December 2019 were investigated retrospectively. Patients who received EdR followed by CRT were deemed the EdR + CRT group and those without CRT were deemed the EdR group. Overall survival (OS), progression-free survival (PFS), and adverse events were evaluated. RESULTS: A total of 41 patients were enrolled. At a median follow-up of 36 mo (range: 1-83), the estimated 1-, 2-, and 3-year cumulative OS rates of patients who underwent EdR plus additive CRT were 92.6%, 85.2%, and 79.5%, respectively, which were higher than those of patients who underwent EdR alone (1-year OS, 83.3%; 2-year OS, 58.3%; 3-year OS, 50%; P = 0.05). The estimated 2-year cumulative PFS rate after EdR + CRT was 85.7%, while it was 61.5% after EdR (P = 0.043). According to the univariate and multivariate Cox regression analyses, early clinical stage (stage ≤ IIB) and additive CRT were potential protective factors for cumulative OS. No severe adverse events were observed during the EdR procedure, and only mild to moderate myelosuppression and radiation pneumonia were observed in patients who underwent additive CRT after EdR. CONCLUSION: EdR plus CRT is an alternative strategy for selective advanced inoperable ESCC patients. |
format | Online Article Text |
id | pubmed-9516645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-95166452022-09-29 Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma Ren, Li-Hua Zhu, Ye Chen, Rong Shrestha Sachin, Mulmi Lu, Qin Xie, Wei-Hua Lu, Tong Wei, Xiao-Ying Shi, Rui-Hua World J Gastrointest Oncol Retrospective Study BACKGROUND: There is no remedial strategy other than definitive chemoradiotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) who are not eligible to undergo surgical treatment. AIM: To introduce a novel therapy called endoscopic debulking resection (EdR) followed by additive chemoradiotherapy (CRT) and evaluate its efficacy and safety. METHODS: Advanced, inoperable ESCC patients between 1 January 2015 and 30 December 2019 were investigated retrospectively. Patients who received EdR followed by CRT were deemed the EdR + CRT group and those without CRT were deemed the EdR group. Overall survival (OS), progression-free survival (PFS), and adverse events were evaluated. RESULTS: A total of 41 patients were enrolled. At a median follow-up of 36 mo (range: 1-83), the estimated 1-, 2-, and 3-year cumulative OS rates of patients who underwent EdR plus additive CRT were 92.6%, 85.2%, and 79.5%, respectively, which were higher than those of patients who underwent EdR alone (1-year OS, 83.3%; 2-year OS, 58.3%; 3-year OS, 50%; P = 0.05). The estimated 2-year cumulative PFS rate after EdR + CRT was 85.7%, while it was 61.5% after EdR (P = 0.043). According to the univariate and multivariate Cox regression analyses, early clinical stage (stage ≤ IIB) and additive CRT were potential protective factors for cumulative OS. No severe adverse events were observed during the EdR procedure, and only mild to moderate myelosuppression and radiation pneumonia were observed in patients who underwent additive CRT after EdR. CONCLUSION: EdR plus CRT is an alternative strategy for selective advanced inoperable ESCC patients. Baishideng Publishing Group Inc 2022-09-15 2022-09-15 /pmc/articles/PMC9516645/ /pubmed/36187386 http://dx.doi.org/10.4251/wjgo.v14.i9.1758 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Ren, Li-Hua Zhu, Ye Chen, Rong Shrestha Sachin, Mulmi Lu, Qin Xie, Wei-Hua Lu, Tong Wei, Xiao-Ying Shi, Rui-Hua Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title | Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title_full | Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title_fullStr | Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title_full_unstemmed | Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title_short | Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma |
title_sort | endoscopic debulking resection with additive chemoradiotherapy: optimal management of advanced inoperable esophageal squamous cell carcinoma |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516645/ https://www.ncbi.nlm.nih.gov/pubmed/36187386 http://dx.doi.org/10.4251/wjgo.v14.i9.1758 |
work_keys_str_mv | AT renlihua endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT zhuye endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT chenrong endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT shresthasachinmulmi endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT luqin endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT xieweihua endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT lutong endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT weixiaoying endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma AT shiruihua endoscopicdebulkingresectionwithadditivechemoradiotherapyoptimalmanagementofadvancedinoperableesophagealsquamouscellcarcinoma |